What was to come was two things - first, an excellent pair of deals with AstraZeneca (AZN) and privately held Cosmo, whereby RedHill acquired Movantik and Aemcolo respectively. Movantik is a revenue-generating naloxegol tablet FDA-approved for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain. Before it was acquired, it was generating around $96 million in annual revenue for AstraZeneca. This is, very roughly, the same amount RedHill will be paying to AstraZeneca as fees and royalties over the next few years. Meanwhile, despite the pandemic, which has badly affected everybody, including this company, it had revenues of $21 million in the November quarter - most of it, I assume, coming from Movantik.
Market Data 
Markets 
AI
